Top

Published in:

01-09-2017 | Maternal-Fetal Medicine

Is there any relationship between adipocytokines and angiogenesis factors to address endothelial dysfunction and platelet aggregation in untreated patients with preeclampsia?

Authors: Zeynep B. Güngör, Hakan Ekmekçi, Abdullah Tüten, Sait Toprak, Gülsel Ayaz, Oktay Çalışkan, Hüseyin Sönmez, Rıza Madazlı, Orkide Donma, Mine Kucur, Turgut Ulutin, Özlem Balcı Ekmekçi

Published in: Archives of Gynecology and Obstetrics | Issue 3/2017

Abstract

Purpose

Preeclampsia is a multisystem disorder and its etiology remains still unclear. Recent hypotheses rely on imbalance between angiogenic and antiangiogenic factors and disruption of endothelial function of spiral arteries. In addition; increased VTE (venous thromboembolism) risk is still unclear in preeclampsia. Our aim was to investigate the relationship between endothelial dysfunction, adipocytokines, platelet function, and vasculogenesis in preeclampsia.

Methods

Plasma angiogenic (PlGF, VEGF), antiangiogenic factors (sflt-1, endoglin) with adipocytokines (leptin, adiponectin, ghrelin), endothelial dysfunction markers (vWF, NO), and platelet function markers (ADP and collagen induced platelet aggregation, P-selectin) were examined in 30 early-onset, 22 late-onset preeclampsia, and 27 healthy pregnants. Enzyme-linked immunosorbent assay (ELISA) was used to determine the serum biomarker levels except NO. NO levels were determined using colorimetric method.

Results

Endoglin, leptin, and vWF levels were increased in preeclampsia (P < 0.001), whereas PlGF, P-selectin (P < 0.001), and col-induced platelet aggregation slope (P < 0.05) were decreased in the same counterpart as compared to healthy pregnants. Endoglin also correlated with sflt-1 in preeclamptic patients.

Conclusion

Increase in the levels of antiangiogenic factors and leptin herewith decline in the level of other angiogenic factor PlGF, did not affect nitric oxide and platelet aggregation markers significantly. Increased levels of vWF and endoglin might be result of endothelial dysfunction, so our findings suggest that an impaired angiogenesis may address endothelial dysfunction, but not platelet aggregation for preeclampsia.

CEMACH (2004) Why mothers die 2000–2002. RCOG Press, London

Sibai BM (2003) Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 102:181–192PubMed

Cnossen JS, Riet GT, Mol BW, van der Post JA, Leeflang MM, Meads CA, Hyde C, Khan KS (2009) Are tests for predicting pre-eclampsia good enough to make screening viable? A review of reviews and critical appraisal. Acta Obstet Gynecol Scand 88:758–765CrossRefPubMed

Tobinaga CM, Torloni MR, Gueuvoghlanian-Silva Pendeloski KP, Akita PA, Sass N, Daher S (2014) Angiogenic factors and uterine Doppler velocimetry in early- and late-onset preeclampsia. Acta Obstet Gynecol Scand 93:469–476CrossRefPubMed

Rasmussen LG, Lykke JA, Sta AC (2015) Angiogenic biomarkers in pregnancy: de ning maternal and fetal health. Acta Obstet Gynecol Scand 94:820–832CrossRefPubMed

Masuyama H, Segawa T, Sumida Y, Masumoto A, Inoue S, Akahori Y, Hiramatsu Y (2010) Different profiles of circulating angiogenic factors and adipocytokines between early- and late-onset pre-eclampsia. BJOG 117:314–320CrossRefPubMed

Seki H (2014) Balance of antiangiogenic and angiogenic factors in the context of the etiology of preeclampsia. Acta Obstet Gynecol Scand 93:959–964CrossRefPubMed

Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, Bossuyt PM, van der Post JA, von Dadelszen P, Mol BW, Pajkrt E, Collaboration EBMCONNECT (2012) Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG 119:778–787CrossRefPubMed

Powe CE, Levine RJ, Karumanchi SA (2011) Preeclampsia, a disease of the maternal endothelium. The role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 123:2856–2869CrossRefPubMed

10.

Aggarwal PK, Chandel N, Jain V, Jha V (2012) The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. J Hum Hypertens 26:236–241CrossRefPubMed

11.

Espinoza J, Uckele JE, Starr RA, Seubert DE, Espinoza AF, Berry SM (2010) Angiogenic imbalances: the obstetric perspective. Am J Obstet Gynecol 203:17.e1–17.e8CrossRef

12.

De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, Anna RD (2008) Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 87:837–842CrossRefPubMed

13.

Venkatesha S, Toporsian M, Lam C (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12:642–649CrossRefPubMed

14.

Toporsian T, Gros R, Kabir MG, Vera S, Govindaraju K, Eidelman DH, Husain M, Letarte M (2005) A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res 96:684–692CrossRefPubMed

15.

Haugen F, Ranheim T, Harsem NK, Lips E, Staff AC, Drevon CA (2006) Increased plasma levels of adipokines in preeclampsia: relationship to placenta and adipose tissue gene expression. Am J Physiol Endocrinol Metab 290:E326–E333CrossRefPubMed

16.

Samolis S, Papastefanou I, Panagopoulos P, Galazios G, Kouskoukis A, Maroulis G (2010) Relation between first trimester maternal serum leptin levels and body mass index in normotensive and pre-eclamptic pregnancies – role of leptin as a marker of pre-eclampsia: a prospective case–control study. Gynecol Endocrinol 26:338–343CrossRefPubMed

17.

Moore LE, Wallace KL, Alexander BT, May WL, Thigpen BD, Bennett WA (2003) Reduced placental perfusion causes an increase in maternal serum leptin. Placenta 24:877–881CrossRefPubMed

18.

Rasouli N, Kern PA (2008) Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 93:S64–S73CrossRefPubMedPubMedCentral

19.

Catalano PM, Hoegh M, Minium J, Huston-Presley L, Bernard S, Kalhan S, Hauguel-De Mouzon S (2006) Adiponectin in human pregnancy: implications for regulation of glucose and lipid metabolism. Diabetologia 49:1677–1685CrossRefPubMed

20.

Nagaya N, Kojima M, Uematsu M, Yamagishi M, Hosoda H, Oya H, Hayashi Y, Kangawa K (2001) Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 280:R1483–R1487PubMed

21.

Body R, Pemberton P, Ali F, McDowell G, Carley S, Smith A, Mackway-Jones K (2011) Low soluble pselectin may facilitate early exclusion of acute myocardial infarction. Clin Chim Acta 412:614–618CrossRefPubMed

22.

Brill A, Fuchs TA, Chauhan AK, Yang JJ, De Meyer SF, Kollnberger M, Wakefield TW, Lammle B, Massberg S, Wagner DD (2011) Von willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood 117:1400–1407CrossRefPubMedPubMedCentral

23.

ACOG Committee on Obstetric Practice (2002) ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol 99:159–167CrossRef

24.

Born GVR (1962) Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194:7–9CrossRef

25.

Tutluoglu B, Gurel CB, Ozdas SB, Musellim B, Erturan S, Anakkaya AN, Kilinc G, Ulutin T (2005) Platelet function and fibrinolytic activity in patients with bronchial asthma. Clin Appl Thromb Hemost 11:77–81CrossRefPubMed

26.

Mc Cabe M, White BA (1999) Platelet protocol research and clinical laboratory procedures printed in the United States of America. Academic Press, Cambridge

27.

Ruggeri ZM (2003) Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 1:1335–1342CrossRefPubMed

28.

Aref S, Goda H (2013) Increased vWF antigen levels and decreased ADAMTS13 activity in preeclampsia. Hematology 18:237–241CrossRefPubMed

29.

Nadar SK, Al YE, Blann AD, Lip GY (2004) Thrombomodulin, von Willebrand factor and E selectin as plasma markers of endothelial damage dysfunction and activation in pregnancy induced hypertension. Thromb Res 113:123–128CrossRefPubMed

30.

Xiong Y, Zhou SF, Zhou R, Yang D, Xu ZF, Lou YT, Guo QS, Hu R, Peng T, Ma D, Li XT (2011) Alternations of maternal and cord plasma hemostasis in preeclampsia before and after delivery. Hypertens Pregnancy 30:347–358CrossRefPubMed

31.

Gilbert JS, Bauer AJ, Gilbert SA, Banek CT (2012) The opposing roles of anti-angiogenic factors in cancer and preeclampsia. Front Biosci 4:2752–4769

32.

Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI (2001) Circulating monocyte platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 104:1533–1537CrossRefPubMed

33.

Moncada S, Palmer RMJ, Higgs EA (1991) Nitric oxide: physiology: pathophysiology and pharmacology. Pharmacol Rev 43:109–142PubMed

34.

Yoneyama Y, Suzuki S, Sawa R, Miura A, Doi D, Otsubo Y, Araki T (2002) Plasma nitric oxide levels and the expression of P-selectin on platelets in preeclampsia. Am J Obstet Gynecol 187:676–680CrossRefPubMed

35.

Rathouska J, Vecerova L, Strasky Z, Slanarova M, Brcakova E, Mullerova Z, Andrys C, Micuda S, Nachtigal P (2011) Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis. Pharmacol Res 64:53–59CrossRefPubMed

36.

Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA, Group CS (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355:992–1005CrossRefPubMed

37.

Blazquez-Medela AM, Garcia-Ortiz L, Gomez-Marcos MA, Recio-Rodriguez JI, Sanchez-Rodriguez A, Lopez-Novoa JM, Martinez-Salgado C (2010) Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med 8:86CrossRefPubMedPubMedCentral

38.

Jezkova K, Rathouska J, Nemeckova I, Fikrova P, Dolezelova E, Varejckova M, Vitverova B, Tysonova K, Serwadczak A, Buczek E, Bernabeu C, Lopez-Novoa JM, Chlopicki S, Nachtigal P (2016) High levels of soluble endoglin induce a proinflammatory and oxidative-stress phenotype associated with preserved NO-dependent vasodilatation in aortas from mice fed a high-fat diet. J Vasc Res 53:149–162CrossRefPubMed

39.

Rathouska J, Nemeckova I, Zemankova L, Strasky Z, Jezkova K, Varejckova M, Nachtigal P (2015) Cell adhesion molecules and eNOS expression in aorta of normocholesterolemic mice with different predispositions to atherosclerosis. Heart Vessels 30:241–248CrossRefPubMed

40.

Laivuori H, Gallaher MJ, Collura L, Crombleholme WR, Markovic N, Rajakumar A, Hubel CA, Roberts JM, Powers RW (2006) Relationships between maternal plasma leptin, placental leptin mrna and protein in normal pregnancy, pre-eclampsia and intrauterine growth restriction without preeclampsia. Mol Hum Reprod 12:551–556CrossRefPubMed

41.

Miehle K, Stepan H, Fasshauer M (2012) Leptin, adiponectin and other adipokines in gestational diabetes mellitus and pre-eclampsia. Clin Endocrin 76:2–11CrossRef

42.

Maruyama I, Nakata M, Yamaji K (2000) Effect of leptin in platelet and endothelial cells. Obesity and arterial thrombosis. Ann N Y Acad Sci 902:315–319CrossRefPubMed

43.

Konstantinides S, Schäfer K, Koschnick S, Loskutoff DJ (2001) Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 108:1533–1540CrossRefPubMedPubMedCentral

44.

Nakata M, Yada T, Soejima N, Maruyama I (1999) Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 48(2):426–429CrossRefPubMed

45.

Nakatsukasa H, Masuyama H, Takamoto N, Hiramatsu Y (2008) Circulating leptin and angiogenic factors in preeclampsia patients. Endocr J 55:565–573CrossRefPubMed

46.

Lu D, Yang X, Wu Y, Wang H, Huang H, Dong M (2006) Serum adiponectina, leptin and soluble leptin receptor in pre-eclampsia. Int J Obstet Gynaecol 95:121–126CrossRef

47.

Naruse K, Yamasaki M, Umekage H, Sado T, Sakamoto Y, Morikawa H (2005) Peripheral blood concentrations of adiponectin, an adipocyte-specific plasma protein, in normal pregnancy and preeclampsia. J Reprod Immunol 65:65–75CrossRefPubMed

48.

Ramsay JE, Jamieson N, Greer IA, Sattar N (2003) Paradoxical elevation in adiponectin concentrations in women with preeclampsia. Hypertension 42:891–894CrossRefPubMed

49.

Dalamaga M, Srinivas SK, Elovitz MA, Chamberland J, Mantzoros CS (2011) Serum adiponectin and leptin in relation to risk for preeclampsia: results from a large case–control study. Metabolism 60:1539–1544CrossRefPubMedPubMedCentral

50.

Odden N, Henriksen T, Holter E, Grete Skar A, Tjade T, Mørkrid L (2006) Serum adiponectin concentration prior to clinical onset of preeclampsia. Hypertens Pregnancy 25:129–142CrossRefPubMed

51.

Ouyang Y, Chen H, Chen H (2007) Reduced plasma adiponectin and elevated leptin in pre-eclampsia. Int J Gynecol Obstet 98:110–114CrossRef

52.

D’Anna R, Baviera G, Corrado F, Giordano D, Di Benedetto A, Jasonni VM (2005) Plasma adiponectin concentration in early pregnancy and subsequent risk of hyprtensive disorders. Obstet Gynecol 106:340–344CrossRefPubMed

53.

Ekmekçi H, Işler I, Sönmez H, Gürel C, Ciftçi O, Ulutin T, Kökoğlu E, Domaniç N, Dirican A (2006) Comparison of platelet fibronectin, ADP-induced platelet aggregation and serum total nitric oxide (NOx) levels in angiographically determined coronary artery disease. Thromb Res 117:249–254CrossRefPubMed

54.

Makino Y, Hosoda H, Shibata K, Makino I, Kojima M, Kangawa K, Kawarabayashi T (2002) Alteration of plasma ghrelin levels associated with the blood pressure in pregnancy. Hypertension 39:781–784CrossRefPubMed

55.

Li ZF, Guo ZF, Yang SG, Zheng X, Cao J, Qin YW (2010) Circulating ghrelin and ghrelin to obestatin ratio are low in patients with untreated mild-to-moderate hypertension. Regul Pept 165:206–209CrossRefPubMed

Title: Is there any relationship between adipocytokines and angiogenesis factors to address endothelial dysfunction and platelet aggregation in untreated patients with preeclampsia?
Authors: Zeynep B. Güngör
Hakan Ekmekçi
Abdullah Tüten
Sait Toprak
Gülsel Ayaz
Oktay Çalışkan
Hüseyin Sönmez
Rıza Madazlı
Orkide Donma
Mine Kucur
Turgut Ulutin
Özlem Balcı Ekmekçi
Publication date: 01-09-2017
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 3/2017
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-017-4461-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Is there any relationship between adipocytokines and angiogenesis factors to address endothelial dysfunction and platelet aggregation in untreated patients with preeclampsia?

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2017

What can we do to reduce the associated costs in induction of labour of intrauterine growth restriction foetuses at term? A cost-analysis study

Association between ERCC2 rs13181 polymorphism and ovarian cancer risk: an updated meta-analysis with 4024 subjects

Melanoma arising in an ovarian cystic teratoma: a systematic review of presentation, treatment, and outcomes

HIV infection or HAART therapy: what is the cause of adverse obstetric outcomes

Postoperative sexual functioning in total versus subtotal laparoscopic hysterectomy: what do women expect?

Effect of epilepsy in pregnancy on fetal growth restriction: a systematic review and meta-analysis